Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted to significantly impact asthma and other respiratory-related conditions, as rising global temperatures lead to longer pollen […]

Search Results

Showing Results for inhalers

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

RT234 is a novel investigational therapy combining inhaled dry powder vardenafil with a proprietary oscillating inhaler, designed for rapid, on-demand relief of breathlessness in patients with pulmonary arterial hypertension (PAH). In a phase 2b CPET study, RT234 demonstrated dose-dependent improvements in peak VOâ‚‚ and dyspnea. As part of our ATS 2025 coverage, Dr Raymond Benza discusses these findings, current treatment limitations, and the next steps toward a phase III clinical trial.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, Professor Irene Higginson, Director of Better Health and Care Futures at King’s College London, discusses the complex challenges of managing breathlessness. She explores non-pharmacological strategies, the value of multidisciplinary care, and how the Breathlessness Support Services at KCL are transforming patient support. Tune in for expert insights and a look at future directions in breathlessness research and care.

Coverage from: Key congresses 2025

Artificial intelligence is no longer a futuristic concept in respiratory care — it's already here, reshaping how we diagnose and manage asthma. In this insightful interview, Dr Alan Kaplan shares how AI is helping bridge long-standing gaps in asthma diagnosis, adherence, and disease control. From apps that can tell the difference between asthma and COPD, to smart inhalers that track medication use and predict exacerbations, Dr Kaplan explores the real-world potential of AI — and the challenges that come with it. He also weighs in on whether AI scribe software can enhance the patient–physician relationship, and what excites him most about the road ahead.

Mark CompleteCompleted
BookmarkBookmarked
Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted ...

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and ...

Mark CompleteCompleted
BookmarkBookmarked
Laurence Désy, Philippe Lachapelle, Simon Couillard

The topic of the carbon footprint of human activities is one frequently discussed worldwide. There have been conscious efforts across multiple fields, including healthcare, to reduce their carbon footprint. In Canada, 4.6% of greenhouse gases (GHG) are manufactured by the healthcare ...

Developed by Touch
Coverage from: AAAAI Highlights

Mepolizumab is a humanized monoclonal antibody used to treat severe eosinophilic asthma. We caught up with Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), a valued member of our Editorial Board for touchREVIEWS ...

Developed by Touch
Coverage from: AAAAI Highlights

Digital inhalers can help patients with asthma and healthcare professionals to track inhaler use and monitor maintenance medication adherence. touchRESPIRATORY were delighted to speak with Dr Giselle Mosnaim (NorthShore University HealthSystem, Evanston, IL, USA; University of Chicago Pritzker School of ...

Developed by Touch
Coverage from: AAAAI Highlights

We caught up with Dr Giselle Mosnaim (NorthShore University HealthSystem, Evanston, IL, USA; University of Chicago Pritzker School of Medicine, Chicago, IL, USA) around the current therapeutic options for asthma and their limitations, and what is known about the clinical ...

Mark CompleteCompleted
BookmarkBookmarked
Rajarajan Anandavelu, Alice M Turner

With the advent of newer drugs targeting the biochemical pathways that lead to cough, it is increasingly important to understand the definition, pathogenesis and management of this symptom. Several specialist bodies also recognize the need for guidance in this area, ...

Mark CompleteCompleted
BookmarkBookmarked

Aspirin-exacerbated respiratory disease (AERD) is a clinical triad of asthma, nasal polyposis and sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). These patients have severe sinopulmonary inflammation, often refractory to standard treatments.1 However, significant advances in the management of ...

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of US Respiratory & Pulmonary Diseases, which aims to provide insightful and topical articles relevant to the everyday practice of busy physicians. COVID-19 continues to dominate headlines worldwide and is the focus of several of ...

Mark CompleteCompleted
BookmarkBookmarked
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta

Strategy reports from both the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20201 and the Global Initiative for Asthma (GINA) 20192 highlight the importance of using the triple combination of inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs), and long-acting muscarinic receptor antagonists (...

Coverage from: ERS Highlights

During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in ...

Coverage from: ERS Highlights

Following his presentation at the ERS Congress, Dr. Kai-Michael Beeh (Insaf Respiratory Research Institute, Wiesbaden, Germany) caught up with us to continue the discussion around green inhalers. Questions 1. Could you give us an overview of the environmental impact of asthma ...

Mark CompleteCompleted
BookmarkBookmarked

Q. Why did Medicaid discontinue coverage of beclomethasone dipropionate in favor of mometasone furoate? A definitive reason for the change has not been divulged. Most formulary changes of this nature are done for economic reasons, the plan being able to ...

Mark CompleteCompleted
BookmarkBookmarked

Underdiagnosis of asthma is an important issue for public health and also at individual level for asthma patients. The 2017 Global Initiative for Asthma used epidemiological surveys to compare the prevalence of asthma symptoms to doctor-diagnosed asthma in low and middle-income ...

Coverage from: ATS Highlights

Nicola A Hanania (Baylor College of Medicine, TX, US) is a valued member of our Editorial Board for US Respiratory & Pulmonary Diseases. He describes how inhalers in asthma and COPD are often misused and this issue can be avoided. ...

Load More...
Close Popup